OTLK (Outlook Therapeutics) Cyclically Adjusted Book per Share: $-45.99 (As of Mar. 2026)


OTLK Outlook Therapeutics Inc OTLK
17 GF Score
Price $1.45
! 5 Warning Signs
View Full Analysis

What is Outlook Therapeutics Cyclically Adjusted Book per Share?

Outlook Therapeutics OTLK -1.69% 17 Cyclically Adjusted Book per Share is $-45.99 as of Mar. 2026. GuruFocus rates OTLK with a GF Score™ of 17/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Outlook Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was $-0.277. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $-45.99 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-04), Outlook Therapeutics's current stock price is $1.45. Outlook Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $-45.99. Outlook Therapeutics's Cyclically Adjusted PB Ratio of today is .


Outlook Therapeutics  (NAS:OTLK) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Outlook Therapeutics Cyclically Adjusted Book per Share Related Terms


Outlook Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Outlook Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics Cyclically Adjusted Book per Share Chart

Outlook Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -65.20 -52.98

Outlook Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -62.82 -61.80 -52.98 -50.00 -45.99

OTLK vs FULC, OBIO, ACIU: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Outlook Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Outlook Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's Cyclically Adjusted PB Ratio falls into.


OTLK
17GF Score
Outlook Therapeutics Inc OTLK
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Outlook Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Outlook Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.277/330.2130*330.2130
=-0.277

Current CPI (Mar. 2026) = 330.2130.

Outlook Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 10.930 241.018 14.975
201609 -36.175 241.428 -49.478
201612 -148.517 241.432 -203.131
201703 -177.841 243.801 -240.874
201706 -187.935 244.955 -253.347
201709 -215.712 246.819 -288.596
201712 -173.438 246.524 -232.316
201803 -225.012 249.554 -297.739
201806 -29.268 251.989 -38.354
201809 -56.641 252.439 -74.092
201812 -49.538 251.233 -65.111
201903 -47.765 254.202 -62.048
201906 -4.642 256.143 -5.984
201909 -11.279 256.759 -14.506
201912 -16.094 256.974 -20.681
202003 -4.573 258.115 -5.850
202006 1.736 257.797 2.224
202009 0.444 260.280 0.563
202012 -1.647 260.474 -2.088
202103 2.379 264.877 2.966
202106 1.459 271.696 1.773
202109 0.522 274.310 0.628
202112 4.354 278.802 5.157
202203 3.185 287.504 3.658
202206 1.778 296.311 1.981
202209 0.769 296.808 0.856
202212 1.228 296.797 1.366
202303 0.817 301.836 0.894
202306 -0.425 305.109 -0.460
202309 -1.110 307.789 -1.191
202312 -1.871 306.746 -2.014
202403 -6.098 312.332 -6.447
202406 -3.575 314.175 -3.757
202409 -3.057 315.301 -3.202
202412 -2.019 315.605 -2.112
202503 -0.987 319.799 -1.019
202506 -0.855 322.561 -0.875
202509 -0.597 324.800 -0.607
202512 -0.597 324.054 -0.608
202603 -0.277 330.213 -0.277

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $-45.99 mean?
Outlook Therapeutics (OTLK) has a Cyclically Adjusted Book per Share of $-45.99 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Outlook Therapeutics and its competitors.
Is Outlook Therapeutics' Cyclically Adjusted Book per Share too high?
Outlook Therapeutics' current Cyclically Adjusted Book per Share is $-45.99. Overall, Outlook Therapeutics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' Cyclically Adjusted Book per Share compare to FULC and OBIO?
Outlook Therapeutics' Cyclically Adjusted Book per Share of $-45.99 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Outlook Therapeutics and its competitors. Outlook Therapeutics's current Cyclically Adjusted Book per Share is $-45.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (OTLK) has a current Cyclically Adjusted Book per Share of $-45.99. The current Cyclically Adjusted Book per Share is $-45.99. Outlook Therapeutics' overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Outlook Therapeutics (OTLK), the current Cyclically Adjusted Book per Share is $-45.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Outlook Therapeutics Business Description

Other Exchanges 41O:Germany
Address 111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
17GF Score

Get the complete analysis for OTLK

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.45
Price